← GENMAB A/S (GNMSF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
GENMAB A/S (GNMSF)
Biotechnology · market cap $21.5B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-06-15 (est.)
Phase 3
Pipeline
18
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Genmab A/S (GNMSF) is a Danish biotechnology company with approximately 3,029 employees and a market capitalization of roughly $18.3 billion. The company operates a multi-asset oncology pipeline spanning several Phase 2 and Phase 3 programs, anchored by epcoritamab in diffuse large B-cell lymphoma (DLBCL). Financial details including cash position, runway, and dilution history are not available in the provided data set.
The catalyst path
- 2027-06-15 (est.)Phase 3 · Epcoritamabimp 9/10
- 2027-06-15 (est.)Phase 3 · Vincristineimp 9/10
- 2027-07-30 (est.)Phase 3 · Acasunlimabimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Epcoritamab | Phase 3 | DLBCL |
| Zalutumumab | Phase 3 | Head and Neck Neoplasms |
| HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma |
| Rina-S | Phase 3 | Non-small Cell Lung Cancer (NSCLC) |
| Investigator's Choice Chemotherapy | Phase 3 | Diffuse Large B-cell Lymphoma |
| Petosemtamab | Phase 3 | Left-sided Colorectal Cancer |
| GDP | Phase 2 | Large Cell Lymphoma, Diffuse |
| Zanubrutinib | Phase 2 | Follicular Lymphoma |
| Tisotumab Vedotin | Phase 3 | Ovary Cancer |
| Loncastuximab Tesirine | Phase 2 | Large B-cell Lymphoma |
| Pegylated liposomal doxorubicin (PLD) | Phase 3 | Platinum-resistant Ovarian Cancer |
| PLD | Phase 3 | Platinum-Sensitive Ovarian Cancer |
| Acasunlimab | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC |
| Vincristine | Phase 3 | Follicular Lymphoma (FL) |
| Investigation agent 2 | Phase 2 | Relapsed Follicular Lymphoma |
| vinorelbine | Phase 3 | Cervical Cancer |
| Doxorubicin Hydrochloride [HCl] | Phase 2 | Non-Hodgkin Lymphoma |
| Leucovorin (Calcium Folinate) | Phase 3 | Colorectal Cancer |
Price & technical context
3-month
+29.1%
6-month
+34.0%
12-month
+22.4%
52-wk range
$232.34–$355.00
vs 50-day MA
+10.3%
vs 200-day MA
+20.3%
Realized vol
34.9%
Max drawdown
-34.0%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GNMSF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.